Trial Profile
Minimal hepatic encephalopathy (MHE) – influence of therapy with rifaximin on MHE and on the intestinal microbiome in patients with liver cirrhosis – the RiMINI-Trial - RiMINI
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Lactulose (Primary) ; Rifaximin (Primary)
- Indications Hepatic encephalopathy; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms RiMINI
- 27 Mar 2018 Status changed from recruiting to discontinued.
- 13 Sep 2016 New trial record